In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Growth

Set Alert for Growth

Getting A Head Start: Medtech VC Aims Earlier Than Ever Before

As the value of medtech deals increases, investors are increasingly looking for earlier opportunities. COVID-19 has added both impetus and new opportunity, with innovators and investors vying to build a position in digital health technologies, such as remote monitoring and digital therapeutics.

Financing Growth

Hunting For Unicorns: Starton Therapeutics

Clinical-stage biopharma Starton Therapeutics is developing continuous delivery systems and transdermal technologies to improve the safety and efficacy of existing cancer medications, and eschewing VC firms in favor of retail investors. Chair and CEO Pedro Lichtinger recently appeared on Unicorn Hunters, an online reality TV show, to pitch the company to celebrity judges, and the public at large.

Business Strategies Commercial

Boehringer Ingelheim: 1885 To Present

Founded in 1885 by Albert Boehringer and now comprised of 146 affiliated companies worldwide and a workforce of roughly 50,000 people, Boehringer Ingelheim has stood the test of time.

Companies BioPharmaceutical

The Vital Role Of Start-Ups In Medtech Innovation

Focus On Switzerland – Part 4: The fragile nature of start-ups belies their value in medtech innovation, and they do not need unnecessary regulatory complications.

Switzerland StartUps and SMEs

Top 10 Best-Selling Drugs Of 2020

One hundred billion dollars. That is the combined revenue of the top 10 pharmaceuticals in 2020, marking the first year in which this threshold has been crossed. AbbVie’s Humira easily retained its lead in 2020 with $20.3bn in sales. Gilead Sciences’ HIV triple combo Biktarvy was the fastest climber, entering the top 10 in eighth place after 53.2% growth in a year, while Avastin, Enbrel and Rituxan fell out of the list.

Companies Growth

Smart Investing: Picking Winners In Gene Therapy

Venture capitalists and industry executives discussed strategies for placing smart bets on emerging gene therapy companies during a recent virtual panel.

Business Strategies Deals

Big Money Spent On Liquid Biopsy Technology In 2021

Deal-making and financing activities are on the rise for liquid biopsy diagnostic products in 2021 despite questions remaining around whether the technology can unseat standard-of-care biomarker and imaging tests.

Commercial Companies

Successful Leadership In Uncertain Times

In conjunction with In Vivo’s Rising Leaders series, a panel of senior executives representing a wide spectrum of the life sciences industry – from large biopharmaceuticals to small biotech and cancer diagnostics – was convened to discuss what it takes to successfully lead during times of uncertainty and upheaval. Insights on communication strategies, navigating team integrations, supporting diversity and inclusion, and getting the most from multi-generational employees rested on a common theme: valuing people and anticipating workforce needs.        

Leadership Growth

Science 37 Blockbuster SPAC Valuation Points To Growth In Decentralized Trials

Expanding partnerships with CROs, the COVID-19 lockdown, an eager FDA and an industry desire for faster and more diverse clinical trial recruiting helped Science 37, a decentralized clinical trial company, nail down plans to go public. Science 37 CEO David Coman spoke with In Vivo about the reasons for going public via SPAC, and why decentralization is a “prerequisite to operating a clinical trial today.” 

Clinical Trials Deals

Laevoroc Oncology Launches With Three-Pronged Strategy

Following early investor conversations, Laevoroc Oncology has split its leading products into three independent subsidiaries to off-set risk and provide greater choice to future partners. While there is no underlying platform technology, CEO Thomas Mehrling believes the subsidiaries all include potential “game-changing medicines.”

Business Strategies C-Suite Speaks

A Peek At The Hand Of Cell, Gene And RNA Therapies

With nearly 3,500 therapies in development globally, and almost $480m in start-up financing in Q1 of 2021 alone, the cell, gene and RNA therapy area is seeing a sharp rise in development and attention. 

Clinical Trials Commercial

Brand Spotlight: Novo Nordisk’s Semaglutide

Novo Nordisk’s semaglutide, a GLP-1 agonist marketed in an injected formulation as Ozempic, and an oral tablet form as Rybelsus, is a success story with the potential for an epic third act. First approved as a treatment for type 2 diabetes, semaglutide is under FDA review as a treatment for obesity, with additional clinical programs in NASH and Alzheimer’s disease. 

Growth Launches
See All
UsernamePublicRestriction

Register